|   In the News

Vertex pays Kymera $70M upfront to discover protein degradation drugs

Vertex Pharmaceuticals is paying $70 million upfront to work with Kymera Therapeutics on the discovery of drugs that drive the elimination of disease-causing proteins. The early-stage deal features more than $1 billion in milestones tied to the success of six programs.

Read more.